IWMF Translational Research Grants

IWMF Translational Research Grants

Status: ACTIVE
Funder: The International Waldenstrom's
Amount: US $500,000 - US $750,000
Last Updated: December 23, 2025

Summary

Overview

About Us The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-driven, nonprofit organization that is dedicated to a simple but compelling vision and mission. Our Vision A World without Waldenstrom’s macroglobulinemia (WM). Our Mission Support and educate everyone affected by Waldenstrom’s macroglobulinemia (WM) to improve patient outcomes while advancing the search for a cure. Applying for a Research Grant IWMF seeks applications for research and clinical studies that will deliver meaningful therapeutic benefits for Waldenstrom macroglobulinemia (WM) patients within the next 3–5 years. Grant amounts range from $250K–$1M over 2–4 years, with a separate award to support young investigators. Working in partnership with our world-class Scientific Advisory Committee, IWMF has developed an updated 2026 Strategic Research Agenda to advance innovative discoveries, support novel clinical trials, and foster collaborations that will continue to revolutionize treatments for WM. IWMF Translational Research Grants IWMF seeks to support translational research studies with a focus on 1) uncovering new features of Waldenstrom macroglobulinemia (WM) biology and cellular vulnerabilities; 2) investigating mechanisms of WM relapse and therapy resistance; and 3) identifying and advancing research on therapeutically novel, therapeutically exploitable targets that represent under-explored opportunities. Such foundational studies should be focused on translational potential and ultimately be driven by the goals of improved patient outcomes and reduction or elimination of disease. Applications for the development of preclinical models, such as organoids with TME elements are also of interest, particularly if they include goals to develop and advance new therapeutics. It is recognized that the applications of new technologies to WM, which often generate descriptive work that lays the groundwork for new therapeutics, are important. Such translational applications will be considered but will be most competitive if clinical relevance can be shown. If the development of a novel therapeutic is proposed, ideally it will have optimized pharmacologic properties (i.e., a lead candidate) that could enable a clinical trial within 3 years. Applications for the development of preclinical models such as organoids with TME elements are also of interest (as done for follicular lymphoma), particularly if they include goals to develop new therapeutics.

Eligibility

You can learn more about this opportunity by visiting the funder's website. Applicants must hold an MD, PhD, or equivalent degree and work in domestic or foreign non-profit organizations, such as universities, colleges, hospitals, or laboratories.Applicants should have an independent research or academic position. Applicants need not be US citizens, and there are no restrictions on applicant age, race, gender, or creed. Applicants can apply for more than one Grant.

Ineligibility

Applicants from non-academic facilities and postdoctoral positions are not eligible.